Brief: C4 Therapeutics Announces FDA Clearance Of Investigational New Drug Application For CFT8919, An Orally Bioavailable BIDAC Degrader Targeting EGFR L858R For Non-Small Cell Lung Cancer
05/07/2023 12:11
July 5 (Reuters) - C4 Therapeutics Inc CCCC.O :
* C4 THERAPEUTICS ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL
NEW
DRUG APPLICATION FOR CFT8919, AN ORALLY BIOAVAILABLE BIDAC™
DEGRADER TARGETING EGFR L858R FOR NON-SMALL CELL LUNG CANCER
* C4 THERAPEUTICS ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL
NEW
DRUG APPLICATION FOR CFT8919, AN ORALLY BIOAVAILABLE BIDAC™
DEGRADER TARGETING EGFR L858R FOR NON-SMALL CELL LUNG CANCER
* C4 THERAPEUTICS- EXPECTS TO INITIATE CLINICAL TRIAL
ACTIVITIES
OUTSIDE GREATER CHINA FOLLOWING COMPLETION OF BETTA
PHARMACEUTICALS' PHASE 1 DOSE ESCALATION STUDY IN GREATER CHINA
Source text for Eikon: ID:nGNX71vqCw
Further company coverage: CCCC.O
(Reuters.Briefs@thomsonreuters.com)